For the bladder cancer patients, median PFS of PTPRD mutations group was not different from WT (over 33.00 vs 16.00 months, HR=0.29, p=0.062, Additional file 2: Fig. S10b). This evidence concerns the gene PTPRD and urinary bladder cancer.